Planning multi-arm screening studies within the context of a drug development program

Statistics in Medicine

Volumn 32, Issue 20, 2013, Pages 3424-3435

  Wason, James M S ^a   Jaki, Thomas ^b   Stallard, Nigel ^c  

^a MRC BIOSTATISTICS UNIT   (United Kingdom)

^b LANCASTER UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

Multi arm multi stage trials; Optimal design; Phase II trials; Screening trials

Indexed keywords

ARTICLE; CLINICAL TRIAL (TOPIC); DRUG DEVELOPMENT; DRUG RESEARCH; DRUG SCREENING; MATHEMATICAL ANALYSIS; MATHEMATICAL COMPUTING; METHODOLOGY; PHARMACEUTICAL CARE; PLANNING; RESEARCH SUBJECT; SAMPLE SIZE; TREATMENT OUTCOME; VALIDATION STUDY;

MULTI-ARM MULTI-STAGE TRIALS; OPTIMAL DESIGN; PHASE II TRIALS; SCREENING TRIALS;

CLINICAL TRIALS AS TOPIC; COCAINE-RELATED DISORDERS; DRUG DISCOVERY; HUMANS; RESEARCH DESIGN; SAMPLE SIZE; TREATMENT OUTCOME;

EID: 84882261227     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.5787     Document Type: Article

References (26)

1. DiMasi J, Hansen R, Grabowski H. The price of innovation: new estimates of drug development costs. Journal of Health Economics 2003; 22:151-185.
2. Stallard N. Optimal sample sizes for phase II clinical trials and pilot studies. Statistics in Medicine 2012; 31:1031-1042.
3. Whitehead J. Designing phase II studies in the context of a program of clinical research. Biometrics 1985; 41:373-383.
4. Whitehead J. Sample sizes for phase II and phase III clinical trials: an integrated approach. Statistics in Medicine 1986; 5:459-464.
5. Julious S. Sample size of 12 per group rule of thumb for a pilot study. Pharmaceutical Statistics 2005; 4:287-291.
6. Sydes MR, Parmar MKB, James ND, Clarke NW, Dearnaley DP, Mason MD, Morgan RC, Sanders K, Royston P. Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial. Trials 2009; 10. DOI: 10.1186/1745-6215-10-39.
7. Royston P, Parmar M, Qian W. Novel designs for multi-arm clinical trials with survival outcomes with an application in ovarian cancer. Statistics in Medicine 2003; 22:2239-2256. DOI: 10.1002/sim.1430.
8. Magirr D, Jaki T, Whitehead J. A generalized Dunnett test for multiarm-multistage clinical studies with treatment selection. Biometrika 2012; 99:494-501. DOI: 10.1093/biomet/ass002.
9. Thall P, Simon R, Ellenberg S. Two-stage selection and testing designs for comparative clinical trials. Biometrika 1988; 75:303-310.
10. Thall P, Simon R, Ellenberg S. A two-stage design for choosing among several experimental treatments and a control in clinical trials. Biometrics 1989; 45:537-547.
11. Posch M, Konig F, Branson M, Brannath W, Dunger-Baldauf C, Bauer P. Testing and estimation in flexible group sequential designs with adaptive treatment selection. Statistics in Medicine 2005; 24:3697-3714. DOI: 10.1002/sim.2389.
12. Friede T, Stallard N. A comparison of methods for adaptive treatment selection. Biometrical Journal 2008; 50:767-781. DOI: 10.1002/bimj.200710453.
13. Stallard N, Friede T. A group-sequential design for clinical trials with treatment selection. Statistics in Medicine 2008; 27:6209-6227. DOI: 10.1002/sim.3436.
14. Bretz F, Konig F, Brannath W, Glimm E, Posch M. Adaptive designs for confirmatory clinical trials. Statistics in Medicine 2009; 28:1181-1217. DOI: 10.1002/sim.3538.
15. Wassmer G. On sample size determination in multi-armed confirmatory adaptive designs. Journal of Biopharmaceutical Statistics 2011; 21:802-817. DOI: 10.1080/10543406.2011.551336.
16. Leiderman DB, Shoptaw S, Montgomery A, Bloch DA, Elkashef A, LoCastro J, Vocci F. Cocaine rapid efficacy screening trial (CREST): a paradigm for the controlled evaluation of candidate medications for cocaine dependence. Addiction 2005; 100(Suppl 1):1-11.
17. Phillips PP, Gillespie SH, Boeree M, Heinrich N, Aarnoutse R, McHugh T, Pletschette M, Lienhardt C, Hafner R, Mgone C, Zumla A, Nunn AJ, Hoelscher M. Innovative trials designs are practical solutions for improving the treatment of tuberculosis. Journal of Infecticious Diseases 2012; 205(Suppl 2):250-257.
18. Hahn T, Bouvier A, Kiêu K. R2cuba: multidimensional numerical integration, 2010. URL http://CRAN.R-project.org/package=R2Cuba, R package version 1.0-6 [Accessed on August 3 2012].
19. R Development Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing: Vienna, Austria, 2011. URL http://www.R-project.org, ISBN 3-900051-07-0 [Accessed on August 3 2012].
20. Nelder J, Mead R. A simplex method for function minimization. The Computer Journal 1965; 7:308-313.
21. Wason J, Magirr D, Law M, Jaki T. Some recommendations for multi-arm multi-stage trials. Accepted by Statistical Methods in Medical Research 2013. DOI: 10.1177/0962280212465498.
22. Genz A, Bretz F. Methods for the computation of multivariate t-probabilities. Journal of Computational and Graphical Statistics 2002; 11:950-971.
23. Jennison C, Turnbull B. Group Sequential Methods with Applications to Clinical Trials. Chapman and Hall: Boca Raton, FL, 2000.
24. Whitehead J, Stratton I. Group sequential clinical trials with triangular continuation regions. Biometrics 1983; 39:227-236.
25. Wason J, Mander A, Thompson S. Optimal multi-stage designs for randomised clinical trials with continuous outcomes. Statistics in Medicine 2012; 31:301-312. DOI: 10.1002/sim.4421.
26. Wason J, Jaki T. Optimal design of multi-arm multi-stage trials. Statistics in Medicine 2012; 31:4269-4279.